Compare Bank of America Corp (BAC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs GSK plc — how do they compare? Bank of America Corp trades at $61.67 (market cap $425.43B), while GSK plc trades at $51.63 (market cap $101.55B). The key difference: Bank of America Corp is far larger — about 4.2× GSK plc's market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| BAC | GSK | |
|---|---|---|
Market Cap | $425.43B | $101.55B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $61.18 |
52-Week Low | $44.92 | $36.20 |
Dividend Yield | 1.85% | 3.5% |
Enterprise Value | — | $122.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $59.50, down 0.28% today, with a bullish technical outlook and strong fundamental support. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.21 exceeding the $1.13 estimate. Revenue growth accelerated to $113.1 billion in 2025, and the P/E ratio of 14 remains attractive. Recent news highlights strategic partnerships and hiring initiatives, reinforcing long-term growth prospects.
BAC presents a favorable investment case with solid profitability, a 64.8% analyst buy rating, and a consensus price target of $63.79 offering 7.2% upside. Risks include sensitivity to interest rates and macroeconomic volatility, but the bank's deposit franchise and capital flexibility provide resilience. The stock is well-positioned for steady appreciation amid supportive technicals and fundamental strength.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
